More on ESAIY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:ESAIY)
Delayed: 6.00 -0.1 (1.64%)
Prev. Close $6.10  
Open$5.97 
52 Wk High$ 
52 Wk Low$ 
Day High$6.03 
Day Low$5.97 
P/E N/A  
EPS$ 
Volume130,598 

Friends, Peers and Foes (?): ESALF, EII BIIB (more...)

Jun 17, 2026 01:15 AM Eisai invests £48M in UK manufacturing with government backing
Jun 17, 2026 01:15 AM Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
May 21, 2026 01:12 PM Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
Apr 21, 2026 08:37 AM Merck and Eisai report failed kidney cancer drug trial results
Apr 21, 2026 08:37 AM Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC
Mar 27, 2026 09:41 AM Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progr
Mar 27, 2026 08:50 AM Eisai and Nuvation Bio get EU validation for lung cancer drug filing
Mar 27, 2026 08:50 AM Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Mar 23, 2026 04:13 AM Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 19, 2026 02:04 AM Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
View All Articles

Entities mentioned with ESAIY

View All Entities